srch

19 rader · 01.12.2021 · Blueprint Medicines and Roche have co-exclusive rights to develop and …

31.12.2021 · About Blueprint Medicines Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease.

Dec 01, 2021 · Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib in the U.S., and Roche has exclusive rights to develop and commercialize pralsetinib outside the U.S., excluding the CStone territory. 5 Received accelerated approval in the U.S. for the treatment of adults with metastatic RET fusion-positive NSCLC ...

Blueprint Medicines Corporation is a precision therapy company focused on genomically defined cancers and hematologic disorders. The Company is focused on ...

At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.

Member Type: Large Biotech/Pharmaceutical Companies. Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to ...

Dec 03, 2021 · Blueprint Medicines Corporation’s (BPMC Quick Quote BPMC - Free Report) lead drug, Ayvakit (avapritinib), was approved by the FDA for the treatment of adult patients with unresectable or ...

Dec 03, 2021 · Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition ...

About Blueprint Medicines Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease.

Dec 09, 2021 · The largest stake in Blueprint Medicines Corporation (NASDAQ:BPMC) was held by Casdin Capital, which reported holding $159.4 million worth of stock at the end of September.It was followed by ...

30.12.2021 · CAMBRIDGE, Mass., Dec. 30, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of ...

Dec 07, 2021 · About Blueprint Medicines Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease.

20 timer siden · Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG-451, a ...

17 timer siden · About Blueprint Medicines . Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of ...

20 timer siden · Blueprint Medicines Completes Acquisition of Lengo Therapeutics - Expands Blueprint Medicines' lung cancer pipeline with LNG-451, a highly selective brain-penetrant precision therapy targeting ...

Blueprint Medicines is a precision therapy company that invents life-changing medicines for cancer and hematologic disorders.

Blueprint Medicines, a precision therapy company, is advancing a deep pipeline of targeted therapies focused on genomically defined cancers, rare diseases ...

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations

GAVRETO is jointly commercialized in the U.S. by Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, under Blueprint Medicines’ collaboration with Roche.

20 timer siden · CAMBRIDGE, Mass., Dec. 30, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG-451, a potential best-in-class oral precision therapy in development for the treatment of non-small cell lung ...

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders.

Blueprint Medicines Corporation develops and distributes biomedical treatments. The Company researches and produces medicines and treatments for cancer ...

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations